Document Detail


The use of botulinum toxin type A in the management of adult-onset focal spasticity: A survey of Australian allied health professionals.
MedLine Citation:
PMID:  22934898     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
BACKGROUND: Recently, the European Journal of Neurology published international consensus statements for the assessment, treatment and aftercare associated with the use of botulinum neurotoxin type A. This survey examined current allied health practice in relation to botulinum neurotoxin type A use in Australia in the light of these guidelines.
METHODS: An electronic questionnaire was distributed to members of neurology groups of the Australian Physiotherapy Association and Occupational Therapy Australia. The questionnaire explored assessment processes used, familiarity with pharmaceutical benefits scheme indications for botulinum neurotoxin type A use, goal setting and outcome measurement, follow-up therapy and access to spasticity management services.
RESULTS: The 123 survey respondents (81 from the Australian Physiotherapy Association - response rate 16.2%, 42 from Occupational Therapy Australia - response rate 6.4%) reported that focal spasticity was a major problem for which botulinum neurotoxin type A was a primary intervention. The Tardieu scale was more frequently used than the modified Ashworth scale (82% vs. 48%). Most therapists (76.3%) reported being confident diagnosing spasticity and its functional implications (84.2%), but fewer were confident discussing referral for botulinum neurotoxin type A with doctors (56.1%). Goals were set in conjunction with the client (93.6%). Barriers to injection and adjunctive therapy (motor training etc.) included waiting times for botulinum neurotoxin type A injection, access to specialist adjunctive therapists and referral for treatment.
CONCLUSIONS: Allied health practitioners in Australia report clinical practice to be closely aligned with international guidelines for the use of botulinum neurotoxin type A in adult spasticity. Therapist confidence in advocating for botulinum neurotoxin type A injection, consistent use of objective measures of spasticity and treatment outcomes and barriers to providing adjunctive therapy need to be addressed.
Authors:
Gavin Williams; John Olver; Stephen de Graaff; Barbara J Singer
Related Documents :
18004908 - Enamel surfaces following interproximal reduction with different methods.
18754368 - How do the partitioning properties of polyhalogenated pops change when chlorine is repl...
4085428 - Critical issues in air pollution epidemiology.
14747598 - Health effects of a sulphur dioxide air pollution episode.
12162528 - Occlusion, prosthodontic treatment, and temporomandibular disorders: a review.
16008638 - Psychometric properties of the brazilian version of the oral health impact profile-shor...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Australian occupational therapy journal     Volume:  59     ISSN:  1440-1630     ISO Abbreviation:  Aust Occup Ther J     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-08-31     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  15420200R     Medline TA:  Aust Occup Ther J     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  257-64     Citation Subset:  IM    
Copyright Information:
© 2012 The Authors Australian Occupational Therapy Journal © 2012 Occupational Therapy Australia.
Affiliation:
Epworth Monash Rehabilitation Medicine Unit, Richmond, Victoria, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Transplantation of adipose-derived stem cells is associated with neural differentiation and function...
Next Document:  Project-based fieldwork: Perspectives of graduate entry students and project sponsors.